ZyVersa Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

11.84 k

Shareholding (Mar 2025)

FII

0.00%

Held by 2 FIIs

DII

99.12%

Held by 1 DIIs

Promoter

0.00%

How big is ZyVersa Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, ZyVersa Therapeutics, Inc. has a market capitalization of 3.06 million and reported net sales of 0.00 million with a net profit of -8.84 million over the last four quarters. Shareholder's funds are 8.52 million, and total assets amount to 20.60 million.

What does ZyVersa Therapeutics, Inc. do?

22-Jun-2025

ZyVersa Therapeutics, Inc. is a micro-cap company in the finance industry, currently reporting a net profit loss of $2 million and a market cap of $3.06 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -61.06%.

Is ZyVersa Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, ZyVersa Therapeutics, Inc. shows a shift to a mildly bearish trend despite some mixed technical indicators, with a year-to-date return of -84.91% compared to the S&P 500's 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Finance

Market cap

USD 1 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.08

Return on Equity

-81.39%

Price to Book

0.20

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.14%

6 Months

-78.3%

1 Year

-86.41%

2 Years

-99.35%

3 Years

-98.63%

4 Years

0.0%

5 Years

0.0%

ZyVersa Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is ZyVersa Therapeutics, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for ZyVersa Therapeutics, Inc. has changed from mildly bullish to mildly bearish. The weekly MACD remains mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the KST is bearish on both weekly and monthly time frames. The RSI shows no signal weekly but is bullish monthly, suggesting mixed signals. The Bollinger Bands are sideways weekly and mildly bearish monthly, indicating a lack of clear direction. Overall, the OBV is mildly bullish weekly but mildly bearish monthly. In terms of performance, the stock has significantly underperformed the S&P 500, with a year-to-date return of -84.91% compared to the S&P 500's 12.22%, and a one-year return of -93.42% versus 17.14%. This stark contrast highlights the stock's current bearish stance despite some mixed technical indicators....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-5.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.08

Sales to Capital Employed (avg)

Tax Ratio

8.78%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.25%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.38

EV to EBIT

-0.17

EV to EBITDA

-0.17

EV to Capital Employed

0.23

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-140.16%

ROE (Latest)

-61.06%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.87%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 21.43% vs 96.43% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-2.80",
          "chgp": "28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-2.80",
          "chgp": "21.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 90.44% vs -597.16% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.10",
          "val2": "-14.40",
          "chgp": "36.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-93.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.40",
          "val2": "-98.30",
          "chgp": "90.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.00

-2.80

28.57%

Interest

0.10

0.00

Exceptional Items

-0.00

0.00

Consolidate Net Profit

-2.20

-2.80

21.43%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 21.43% vs 96.43% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.10

-14.40

36.81%

Interest

0.30

0.00

Exceptional Items

0.00

-93.30

100.00%

Consolidate Net Profit

-9.40

-98.30

90.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 90.44% vs -597.16% in Dec 2023

All Annual Results

Company CV

About ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc.

Finance

No Details Available.

Company Coordinates

No Company Details Available

ZyVersa Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is ZyVersa Therapeutics, Inc.?

Watch in Real-Time

What does ZyVersa Therapeutics, Inc. do?

Is ZyVersa Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is ZyVersa Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About ZyVersa Therapeutics, Inc.

Company Coordinates